Chimeric Therapeutics (CHM) investor relations material

Investment highlights

• Three Phase 1 clinical trials underway at six leading US centers under three FDA INDs.

• Multiple clinical updates expected within the next six months.

• Leadership team experienced in cell therapy clinical development.

• First CDH17 CAR-T therapy in clinical trials, with robust patent portfolio.

• Market cap approximately $3.1 million, share price at $0.036.

Clinical pipeline and progress

• Two novel cell therapies in portfolio: CHM CDH17 CAR-T and CHM CORE-NK, each in clinical trials.

• CHM CDH17 CAR-T is the first of its kind in clinical trials globally, with 14 patients treated and no safety issues to date.

• CHM CORE-NK is an off-the-shelf allogeneic NK cell therapy, with positive Phase 1A results in AML and ongoing Phase 1B trials.

• Manufacturing for CHM CDH17 has achieved 15/15 successful GMP-compliant runs.

• Dose escalation and expansion ongoing for both programs, with first-line dosing underway in AML.

Clinical results and safety

• CHM CDH17 CAR-T showed complete eradication of tumors in preclinical mouse models with no relapse.

• In clinical trials, anti-tumor activity and tumor shrinkage observed, with no off-target effects or unexpected safety issues.

• CHM CORE-NK achieved 15/25 complete responses in frontline AML patients, with no safety issues reported.